Introduction
Among human PBMCs, three distinct B-cell subsets can be identified on flow cytometry, i.e. naive B, memory B and plasmablasts, which have been studied extensively in health and disease (1, 2) . De-regulated B cells and antibody-forming plasma cells are particularly important targets for treatment of several autoimmune diseases such as systemic lupus erythematosus (SLE), because the therapeutic effect on SLE of rituximab, a CD20-targeting chimeric mAb, is considered to comprise elimination of activated B cells and auto-antibodyproducing cells (1) (2) (3) (4) (5) (6) . In order to develop more efficient therapeutic strategies for autoimmune diseases, it is important to elucidate the mechanism underlying deregulation of B cells and plasma cells and to find specific target molecules that can modulate B-cell activities to prevent auto-antibody production.
In this context, the recently newly identified CD20 + CD27 + CD43 + B (CD43 + B) cells (or proposed human B1 cells) among PBMCs, which may correspond to murine B1 cells (7, 8) , have attracted much attention as to how this potentially novel B-cell subset is related to other B-cell subsets and how it is correlated to autoimmune diseases like SLE, because at least in a murine system, B1 cells are considered to be the earliest onset cells among B-lineage cells, and not only a major source of polyspecific and weakly autoreactive IgM natural antibodies (9, 10) , but also a regulator of IgG auto-antibody producers (11, 12) . Therefore, it would be interesting to determine the position of CD43 + B cells in relation to other known B-cell subsets. The initial series of original reports on CD43 + B cells (7, 8) , however, raised questions as to possible contamination by monocytes and/or T cells of the CD20   +   CD27   +   CD43 + cell gate, due, in part, to incomplete elimination of doublet cells and CD3 + T cells (13) (14) (15) , followed by responses demonstrating that the newly identified population is truly a B-cell subset (8, 16) . More recently, CD43 + B cells were found to possess a preplasmablast phenotype based on the results of a functional analysis and a gene expression profile (17) , although this is controversial (18) . Therefore, it is critically important to precisely define the CD43 + B-cell subset and to determine its developmental position. As keys to dissect this, we were particularly interested in examining possible differences in Ig-secreting ability as well as in the expression profiles of characteristic B-cell regulatory receptors in B-cell subsets, including a unique inhibitory IgG FcR, FcγRIIB (19, 20) , sialic acid-binding Ig-like lectin (Siglec)-2 (or CD22), and Siglec-10 (21-23), and inhibitory isoforms of Ig-like transcript/ leukocyte Ig-like receptor (ILT/LILR, also known as LIR/MIR/ CD85) (24) (25) (26) (27) .
The aim of the present study was to determine the characters of CD43 + B cells among PBMCs from healthy individuals and to clarify their relationship with other B subsets by analyzing any differences in the expression profile of B-cell markers including B-cell regulatory receptors and B-cell/ plasma cell signature genes and in Ig-secreting ability, with reference to the frequencies of B-cell subsets in SLE patients. We found that CD43 + B cells from healthy donors show phenotypic characteristics unexpectedly close to memory B cells but not those of plasmablasts, while we also found a more close developmental relationship to plasmablasts than that of memory B cells to plasmablasts in an in vitro differentiation experiment, as detailed in this study.
Methods

Donors and peripheral blood samples
Twenty-six healthy donors (aged 22-44; 18 males and 8 females) were recruited from our laboratory staff and Tohoku University Hospital with written informed consent. We also collected blood samples with written informed consent from outpatients (four males aged 27-78 and six females aged 22-67) of the Tohoku University Hospital. Patients were diagnosed as SLE defined with the 1997 revised American College of Rheumatology classification criteria for SLE. All patients had active disease (SLEDAI-2K > 6) and elevated anti-DNA antibody levels in sera at the time samples were obtained. Three of the 10 patients had lupus nephritis and two had central nervous system symptoms. Blood samples (10-40 ml blood/each time) were obtained by venipuncture using Venoject II vacuum blood collector tubes (Terumo Inc., Tokyo, Japan). This study was approved by the Ethics Committee of Tohoku University Graduate School of Medicine and performed in accordance with a statement on ethical principles for medical research involving human subjects made in the Declaration of Helsinki.
Reagents and antibodies
Pancoll Human and Ficoll-Paque PLUS for the purification of PBMCs were obtained from PAN-Biotech GmbH (Aidenbach, Germany) and GE Healthcare Bio-Sciences AB (Uppsala, Sweden), respectively. FITC-labeled mouse anti-human CD43 (clone 1G10), PerCP-Cy5.5-labeled mouse anti-human CD19 (SJ25C1) and V500-labeled mouse anti-human IgD (IA6-2) were purchased from BD Biosciences (San Jose, CA, USA). Allophycocyanin (APC)-Cy7-labeled mouse anti-human CD20 (2H7), Brilliant Violet 510-labeled mouse anti-human CD20 (2H7), APC-labeled mouse anti-human CD27 (O323), Pacific Bluelabeled mouse anti-human CD3 (HIT3a), PerCP-Cy5.5-labeled mouse anti-human CD19 (HIB19), Brilliant Violet 421-labeled mouse anti-human CD38 (HIT2), PE-Cy7-labeled mouse antihuman CD38 (HIT2), PE-Cy7-labeled mouse anti-human CD69 (FN50), PE-Cy7-labeled mouse anti-human CD5 (UCHT2), PE-labeled mouse anti-human IgM (MHM-88), PE-labeled rat anti-human CD32 (FUN-2), PE-labeled mouse anti-human CD85j (ILT2/LILRB1) (GHI/75), PE-labeled rat anti-human CD85d (ILT4/ LILRB2) (42D1) and PE-labeled rat anti-human CD85a (ILT5/ LILRB3) (MKT5.1) were obtained from BioLegend (San Diego, CA, USA). PE-labeled mouse anti-human CD85k (ILT3/LILRB4) (ZM4.1) was obtained from eBioscience (San Diego, CA, USA).
Cell separation
Mononuclear cells were obtained by density gradient separation using Pancoll Human and Ficoll-Paque PLUS. We added an equal volume of PBS to the fresh blood samples, layered the diluted blood in 4-ml increments onto 3-ml Pancoll or Ficoll in a 15-ml centrifugation tube (Corning, Corning, NY, USA), and then centrifuged it at 430 × g for 40 min at room temperature. The resultant mononuclear cell layers were collected and washed twice with PBS.
Flow cytometry analysis and cell sorting
The PBMCs were subjected to immunofluorescent staining and sort-purified on a FACS Canto (BD Biosciences) and a FACSAria (BD Biosciences). The data were analyzed with FACS Diva (BD Biosciences) and FlowJo software (Tree Star, Inc., Ashland, OR, USA). Doublet cells were removed by gating on forward scatter (FSC)-width (FSC-W) versus FSCheight (FSC-H) according to the manufacturer's instruction. Monocytes were gated based on FSC area (FSC-A) versus SSC area (SSC-A) characteristics. IL-15 (PeproTech) for 4 days, as described previously (28) .
B-cell culture and stimulation
Enzyme-linked immunosorbent assay
ELISAs were performed to measure total IgM, IL-6 and IL-10 using Human IgM ELISA Quantitation Set (Bethyl Lab, Inc., Montgomery, TX, USA), Human IL-6 ELISA Ready-SET-Go! (eBioscience) and Human IL-10 ELISA Ready-SET-Go! (eBioscience). All ELISAs were performed using 96-well half-area microplates (Greiner Bio-one) according to the manufacturer's directions.
ELISPOT
Ig secretion was determined by ELISPOT assaying, using MultiScreen-IP plates (Millipore, Billerica, MA, USA) coated with goat anti-human IgG-Fc coating antibodies (Bethyl Lab) or human IgM coating antibodies (Bethyl Lab), and blocked with RPMI medium. 1 × 10 3 sort-purified B cells were cultured in 100 μl RPMI medium at 37°C for 12 h, after which the plates were treated with HRP-conjugated goat anti-human IgG detection antibodies or HRP-conjugated human IgM detection antibodies and developed with 3-amino-9-ethylcarbazole. Spots were examined under a fluorescence microscope and analyzed with ImageJ (National Institute of Mental Health, Bethesda, MD, USA).
Quantitative real-time PCR analysis
Total RNA was isolated using a NucleoSpin RNA XS kit (Macherey-Nagel, Dueren, Germany) and subjected to cDNA synthesis with ReverTra Ace (Toyobo, Osaka, Japan). The cDNA was analyzed by quantitative PCR with SYBR GreenER qPCR SuperMix (Life Technologies) on a CFX Connect Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). The primers were used as previously described (29) : BCL6 (forward, 5′-GAGCTCTGTTGATTCTTAGAACTGG-3′; reverse, 5′-GCCTTGCTTCACAGTCCAA-3′), PAX5 (forward, 5′-ACGCTGACAGGGATGGTG-3′; reverse, 5′-CCTCCAGGA GTCGTTGTACG-3′), PRDM1 (forward, 5′-AACGTGTGGGTA CGACCTTG-3′; reverse, 5′-ATTTTCATGGTCCCCTTGGT-3′) and XBP1 (forward, 5′-CCGCAGCACTCAGACTACG-3′; reverse, 5′-TGCCCAACAGGATATCAGACT-3′). The relative gene expression is normalized by GAPDH (forward, 5′-CTCTGCTCCTCCTGTTCGAC-3′; reverse, 5′-ACGACC AAATCCGTTGACTC-3′).
Statistical analysis
Statistical analysis was performed using Microsoft Excel for Mac 2011 software version 14.2.3 (Microsoft Corp., Seattle, WA, USA). Data are displayed when appropriate as means ± SD. Data were compared for statistical differences using Student's t-test with two-tailed analysis. P values are shown in the relevant figures. P < 0.05 was considered as statistically significant.
Results
CD43 + B cells are differently gated from plasmablasts
We first attempted to isolate CD43 + B cells from PBMCs prepared from healthy volunteers, essentially according to the standard protocol described previously (Fig. 1A) (7, 8) . Special care was taken so as to eliminate contaminating T cells and monocytes as much as possible (13) (14) (15) by initially staining CD3 and CD19 in addition to standard CD20, CD27 and CD43 (7, 8, 30 Because the CD43 + B-cell gate is adjacent to that of plasmablasts, we examined for possible contamination by plasmablasts of the CD43 + B-cell compartment by analyzing the expression of CD38, which is highly expressed on plasmablasts (2, 32) . The flow cytometric profiles of CD38 expression in both the IgD − and IgD + CD43 + B cells (see Fig. 1C ) were low and comparable to those in naive and memory B cells (Fig. 1B, left) . A direct comparison of the CD38 expression levels between CD43 + B cells and plasmablasts by flow cytometry also indicated that the expression level of CD38 on CD43 + B cells was much lower than that in plasmablasts (Fig. 1B, right) . These results indicate that contamination by plasmablasts, if any, of the CD27 + CD43
+ fraction was not substantial.
Since the CD43 + B-cell gate is also adjacent to the naive and memory B-cell gates, we examined for possible differences in the CD43 + B cells by analyzing the expression of other B-cell markers, i.e. IgM, IgD and CD5. As shown in 
Distinguishable profiles of inhibitory receptor expression in CD43 + B cells and plasmablasts but not memory B cells
The defined CD43 + B-cell gate enabled us to precisely compare cell-surface regulatory molecules on individual B-cell subsets. Thus, we next tried to find any differences in the expression profiles of regulatory receptors including inhibitory isoforms of ILT/LILR, whose murine homolog is Paired Ig-like receptor (Pir)B (33, 34), a negative regulator of auto-antibody production (35) . In contrast to monocytes expressing the four inhibitory-type ILT/LILR isoforms, ILT2-5/LILRB1-B4, it is believed that B cells preferentially express only ILT2/LILRB1, a close homolog of murine PirB (24, 25, 36, 37) . Consistent with this notion, among B cells we detected only ILT2/LILRB1 on naive, memory and CD43 + B cells at comparable levels (Fig. 2) . Unexpectedly, we found that ILT3/LILRB4 expression was strong on plasmablasts but not on any other B-cell subsets including CD43 + B cells (Fig. 2) .
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We also found strong expression of CD32 (FcγRIIB), Siglec-10 and Siglec-2 on CD43 + B cells (Fig. 2) , suggesting that these receptors could be physiologically important for the functional regulation of this type of B cells. Interestingly, while the FcγRIIB level on CD43 + B cells was not significantly different from those on naive B cells and plasmablasts, Siglec-10 and -2 had almost totally disappeared on plasmablasts, whereas CD43 + B cells carried them at comparable levels to those on memory B cells (Fig. 2) . Comparable expression of Siglec-2 among the CD43 + B cells, and naive and memory B cells has also been observed (7, 16 (Fig. 3A) by CD43 + B cells in the absence of the TLR9 stimulator was only marginal or under the detection limit in two to three independent experiments. In the presence of 0.2 μM CpG-ODN, the IgM and IL-10 secretion by CD43 + B cells was occasionally higher than that by memory or naive B cells, but it was not the same for every specimen tested. To confirm the poor secretion of Ig by the CD43 + B-cell subset, we measured the frequencies of IgM-and IgG-secreting cells by ELISPOT among CD43 + B cells and in the plasmablast fraction, as a positive control. As shown in Fig. 3(B) , the plasmablast subset prepared from three different individuals was found to be consistently rich in IgM-and IgG-secreting cells, but these frequencies in CD43 + B cells were markedly low. The naive and memory B-cell fractions also did not contain notable numbers of Ig-secreting cells. We concluded that, like memory and naive B cells, CD43 + B cells are not active secretors of Igs and IL-10 in vitro in the absence of a stimulator. On the basis of the results shown in Figs 1-3 , we considered at this stage that this B-cell population might be more pertinent to be termed CD43 + B cells with phenotypic markers very similar to memory B cells but not human B1 cells.
The size of the CD43 + B-cell compartment is not significantly altered in SLE
We were next interested in examining the CD43 + B-cell compartment in PBMCs from SLE patients. In SLE, the total number of PBMCs is reduced and the plasmablast compartment is enlarged, while the memory B-cell compartment is reduced (1, 32) . We examined the size of each B-cell population in SLE under our flow cytometric settings. We observed a significant reduction in the total number of PBMCs (Fig. 4A) , and a reduction of the frequency of CD43 − memory B cells ( Fig. 4B and  C) , and a marked increase in the plasmablast frequency in total PBMCs (Fig. 4B ) and in CD19 + cells (Fig. 4C ) compared with in healthy subjects. Unexpectedly, irrespective of these changes in SLE, the frequency of CD43 + B cells among total PBMCs (Fig. 4B) as well as in CD19 + cells (Fig. 4C ) was comparable in SLE and healthy subjects. These results indicated that, in SLE, the size of CD43 + B-cell subset is not significantly changed regardless of a reduction of CD43 − memory B cells or an increase of plasmablasts.
A moderate correlation in the frequencies of CD43 + B cells and plasmablasts in healthy subjects
We examined the frequency correlations between B-cell compartments in healthy subjects as well as in SLE patients (Fig. 5 and Supplementary Figure S1 , available at International Immunology Online). Obviously, care should be taken when we interpret the positive or negative correlation in SLE subjects, because the donor ages varied particularly in SLE patients, and the aged patients tended to have fewer CD43 + B cells than the younger patients (Supplementary Figure S1A , available at International Immunology Online). We observed, however, that the correlation profiles in SLE patients did not change markedly when we omitted the plots of the three patients aged over 60 (data not shown). In healthy subjects, while we did not observe remarkable correlations of the frequencies of CD43 + B cells to those of total CD19 + B (Fig. 5A ), naive B (Fig. 5B) and memory B cells (Fig. 5C ), we noted a moderate correlation between the frequencies of CD43 + B cells and plasmablasts (Fig. 5D, left) . In SLE, interestingly, this correlation was not clear (Fig. 5D, right) , but instead a correlation was observed between the CD43 + B cells and the memory B cells (Fig. 5C, right) . Thus, it was suggested that showing the expression levels of a series of inhibitory receptors on each B-cell population as well as on monocytes as a control (A). In the graphs, data are means ± SD for three independent experiments. While monocytes expressed all of the four types of LILRB examined, both IgD − and IgD + CD43 + B cells expressed only LILRB1 at similar levels to those in other B-cell populations, but were negative for LILRB2, B3 and B4 (A), such an expression preference for LILRB1 being a hallmark of B-lineage cells. Higher expression was found for LILRB4 on plasmablasts than the other B-cell subsets including CD43 + B cells (B). The expression of FcγRII, Siglec-10 and CD22 (A and B) was found on both the IgD − and IgD + CD43 + B cells. *P < 0.05; ***P < 0.005; ns, not significant.
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CD43 + B cells are related to plasmablasts in healthy subjects, although CD43 + B cells in healthy subjects were shown to be quite similar to memory B cells phenotypically and different from plasmablasts, as described above.
CD43 + B cells develop into plasmablast-like cells more efficiently than memory B cells upon stimulation in vitro
To determine if the possible relation between CD43 + B cells and plasmablasts is the developmental proximity between them, we sort-purified CD43 + B cells and CD43 − memory B cells from PBMCs of healthy subjects (Fig. 6A) and incubated them for 4 days in vitro in the presence of CpG-ODN, CD40L, IL-2, IL-10 and IL-15 (28) . Under this culture condition, the recoveries of viable cells at day 4 were comparable between the cultures of CD43 + B cells and memory B cells (Fig. 6B) . We found that CD43 + B cells showed a more efficient development into CD20 low CD27 high CD43
high plasmablast-like cells than memory B cells did (Fig. 6C) . CD43 + B cells were developed from the CD43 − memory B-cell cultures, but the expression level of CD43 was lower than the CD43 + B-cell cultures (Fig. 6D) . Also, LILRB4 + cells were developed from both CD43 − memory B and CD43 + B-cell cultures but the frequencies of LILRB4 + cells as well as the expression levels of LILRB4 were higher in CD43 + B-cell cultures ( Fig. 6C and D) . Expression levels of CD20 and CD38 were significantly lower and higher in CD43 + B-cell cultures, respectively, than CD43 − B-cell cultures (Fig. 6E) . At day 4, frequencies of LILRB4 + cells were consistently higher in CD43 + B-cell cultures than CD43 − memory B-cell cultures (Fig. 6E) . LILRB4 + cells at day 4 were largely CD20 low CD27 high CD43 high , indicating that they are plasmablasts as judged by the markers (Fig. 6C, R2 gated cells) . These results suggest that CD43 + B cells are more closely related to plasmablasts developmentally than are memory B cells.
We also determined an expression profile of B-cell and plasma cell signature genes in CD43 + B cells from healthy donors to confirm a possible developmental proximity of CD43 
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CD43
+ B cells for their gene expression of BCL6 and PAX5 as B-cell signatures and PRDM1 (or BLIMP1) and XBP1 as plasmablast/plasma cell signatures revealed that CD43 + B cells express BCL6 and PAX5 mRNAs at lower levels than memory B cells (Fig. 6F) . We found that CD43 + B cells also express PRDM1 mRNA at a significantly higher level than memory B cells but less abundantly than plasmablasts, while their XBP1 expression is significantly lower than plasmablasts as are those of naive and memory B cells. PRDM1 and XBP1 expression levels in CD43 + B cells after 4-day culture in the presence of stimulators and cytokines described above were significantly higher than those of memory B cells (Fig. 6F) . These results support our notion that CD43 + B cells are more closely related to plasmablasts developmentally than are memory B cells.
Discussion
In this study, we aimed at characterizing a discrete population of + B cells with nearly identical inhibitory receptor profiles to those of memory B cells and that also showed inactive Ig and IL-10 secretion, and thus we suggest that this B-cell population is more pertinent to be called as CD43 + B cells with phenotypic markers similar to memory B cells rather than human B1 cells. We also additionally found, however, a developmental proximity of CD43 + B cells to plasmablasts in an in vitro development experiment. CD43 + B cells were initially proposed to be human B1 cells, which could be a source of auto-antibodies as to health and disease like those in mice (7) . The initial series of original reports on the proposed B1 cells (7, 8) + cells in healthy donors and SLE patients. PBMCs were prepared from healthy donors and SLE patients (A), and analyzed by flow cytometry, and then the size of each B-cell subset as the frequency in total PBMCs (B, means ± SD, n = 9 for healthy and n = 10 for SLE) and that in CD19 + cells (C, means ± SD, n = 9 for healthy and n = 10 for SLE) was calculated. *P < 0.05, **P < 0.01, ***P < 0.001.
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to incomplete elimination of doublet cells and CD3 + T cells (13) (14) (15) , followed by responses demonstrating that the newly identified B-cell population is truly a B-cell subset (8, 16) . Using a more stringent gating strategy to eliminate T cells and monocytes, we also identified a small but discrete B-cell lineage population, as judged from its exclusive ILT2/LILRB1 expression (Fig. 2) in addition to the CD3 − CD19 + CD20 + phenotype (Fig. 1) .
The proposed B1 subset was shown to be subdividable into two discrete populations (38) , one being CD11b + B1 or 'orchestrator B1 cells', which can stimulate allogeneic T-cell proliferation and also can suppress CD3-activated T cells via IL-10 secreted by the CD11b + B1 cells, and the other being CD11b − B1 cells or 'secretor B1 cells', which spontaneously secrete IgM antibodies. Later, other groups (39, 40) tried to find some discrete characters of the proposed B1 cells and their relation to common variable immunodeficiencies. Each group identified a proposed B1 cell population, but some of the characters initially reported (7) were not confirmed (39, 40) . We failed to observe spontaneous and active production of Ig or IL-10 by CD43 + B cells in vitro (Fig. 3) . Concerning the subcomponents of the proposed B1 cells, it has been documented that the B1 cell fraction comprises IgG + or IgA + cells in addition to IgD + cells, arguing that this fraction may be contaminated by activated CD38 + plasma cells or their precursors (13, 14) . Analysis of our CD43 + B cells indicated that they could be subdivided into IgD − cells, the latter also being dominant (Fig. 1) . The CD38 low profile of CD43 + B cells (Fig. 1 ) indicated successful elimination of substantial contamination by CD38 + plasmablasts of the subset. It has been recently argued that the proposed human B1 cells exhibit a preplasmablast phenotype (17) . They showed that CD20 + CD27 +
CD43
+ B cells could develop from memory B cells upon stimulation with R-848, a ligand for TLR7 and TLR8, and IL-2 for 5 days. They also showed that the proposed B1 cells could become a substantial number of CD20 − plasmablasts and a small number of plasma cells upon stimulation with R-848, IL-2, IL-10, IL-15 and IL-6 for 5 days. Microarray analysis of high-expression gene profiles in the proposed B1 cells, memory B cells and plasmablasts also suggested that the proposed B1 cells were closer to plasmablasts than memory B cells. On the basis of these data, they concluded that the proposed B1 cells possess preplasmablast phenotypes that are inconsistent with murine B1 cells, although controversy still exists (18, 41, 42) . In our present study, the data on marker and Ig/cytokine secretion profiles suggest that CD43 + B cells are a B-cell subset with phenotypes nearly identical to those of memory B cells. However, we noted a moderate correlation in the frequencies of CD43 + B cells and plasmablasts in healthy subjects (Fig. 5D) , which prompted us to examine the developmental proximity of CD43 + B cells to plasmablasts by means of quantitative PCR analysis of signature genes and in vitro induction of plasmablasts from CD43 + B cells by culturing them with a TLR9 ligand, CD40L and cytokines ( were determined by quantitative PCR. The relative expression of transcripts was normalized to GAPDH. Data are means ± SD for three independent experiments. *P < 0.05, **P < 0.01.
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B cells as well as the naive and memory B-cell subsets was anticipated, because ILT2/LILRB1 is the sole ILT/LILR isoform expressed on human B cells (27, 37, 43) . One of the interesting findings in our present study was that plasmablasts exhibited striking induction of ILT3/LILRB4 in addition to the B-lineage cell signature, ILT2/LILRB1 expression (Fig. 2) , although a preceding microarray-based study revealed significant overexpression of ILT3/LILRB4 mRNA in polyclonal plasmablastic cells compared with in mature plasma cells (44) . We found that ILT3/LILRB4 is a useful marker not only for plasmablasts in PBMCs but also for plasmablasts in culture, as is the case for CD38, as demonstrated in an in vitro differentiation experiment shown in Fig. 6 . ILT2/LILRB1 is expressed on B cells, a subset of T cells, NK cells, monocytes and macrophages, and dendritic cells, and is one of two human orthologs of murine PirB (25, 33, 34, 43, 45) . Although ILT4/LILRB2 is another ortholog of PirB in terms of structural and functional similarities, it is not expressed on human B cells but on other cells in which ILT2/LILRB1 co-exists. The ligands for ILT2/ LILRB1 are multiple, including HLA-A, B, C, E and F (43), cytomegalovirus protein UL18 (26) , neurite outgrowth inhibitor protein or Nogo, myelin-associated glycoprotein or MAG, and oligodendrocyte myelin glycoprotein or OMgp (46) . ILT4/ LILRB2 ligands include also HLA class I molecules, and three kinds of neuronal myelin proteins, Nogo/MAG/OMgp, and several angiopoietin-like proteins (Angptls), a family of seven secreted glycoproteins (47) , but ILT4/LILRB2 does not bind UL18. ILT3/LILRB4 is found on monocytes/macrophages and dendritic cells, but the ligand for ILT3/LILRB4 is currently not known. There has been no extensive study on the physiological role of ILT3/LILRB4, except for ones showing a modulatory effect of this receptor in making dendritic cells tolerogenic (48, 49) . Our finding of surface ILT3/LILRB4 expression on plasmablasts suggests that this receptor with cytoplasmic signal-inhibiting motifs plays a modulatory role in some developmental stages of plasmablasts or plasma cells, which will home to peripheral tissues and bone marrow where they constitutively produce antibodies.
In conclusion, CD43 + B cells among PBMCs possess very similar phenotypic characteristics to those of memory B cells, while they exhibit developmental proximity to plasmablasts more than memory B cells do. We suggest that CD43 + B cells are a potent precursor population en route to plasmablasts or an activated B-cell subset or both in healthy individuals. Whether the CD43 + B-cell subset is always at an intermediate stage of the development from memory B cells to plasmablasts, or a discrete, independent population with a potential to become plasmablasts in health and disease remains an open question.
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